Journals / Van Tıp Dergisi / 2022 / Cilt: 29 - Sayı: 3

The Relationship Between Pet - CT and Tumor Features in Patients With Breast Cancer

Meme Kanserli Hastalarda Pet - BT ile Tümör Özellikleri Arasındaki İlişki

Pages
337–343
Publication Date
2022-11-06
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The relationship between tumor characteristics and FDG uptake can be used as a predictive marker for individualized treatment in the future.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Introduction: Breast cancer is the most common cancer and major cause of cancer death in women worldwide.
📊
Key Findings & Data:In our study, we planned to investigate the relationship between 18 Ffluoro- 2-deoxy-D-glucose (18 F-FDG) uptake and characteristics of the tumor.
💡
Conclusion & Impact:The relationship between tumor characteristics and FDG uptake can be used as a predictive marker for individualized treatment in the future.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Introduction: Breast cancer is the most common cancer and major cause of cancer death in women worldwide. The importance of usage positron emission tomography (PET) – computed tomography (CT) in oncology is increasing. In our study, we planned to investigate the relationship between 18 Ffluoro- 2-deoxy-D-glucose (18 F-FDG) uptake and characteristics of the tumor. Material and Method: The medical records of 414 patients who applied to our oncology clinic with the diagnosis of breast cancer and underwent PET-CT were analyzed retrospectively. Patients with breast cancer aged between 18-90 years were included in the study. Patients with secondary malignancy, mentally unstable, younger than 18 years of age and older than 90 years of age were excluded from the study. FDG uptake was investigated according to molecular subtypes, tumor sizes, body mass index and proliferation indices. Findings: The mean age of 414 patients included in the study was 48,8 years. The vast majority of patients had invasive ductal carcinoma. While 86 patients were in the metastatic stage at the time of diagnosis, 327 patients had local or locally advanced disease. In the study, there was a correlation between the increase in Ki-67 and the increase in FDG uptake and it was statistically significant. Conclusion: In the study, those with larger tumor size had more FDG uptake. Likewise, increased proliferation index and invasive ductal carcinoma had higher FDG uptake. The relationship between tumor characteristics and FDG uptake can be used as a predictive marker for individualized treatment in the future.

Özet

Amaç: Meme kanseri dünya çapında kadınlarda en sık görülen ve en sık ölüme yol açan kanserdir. Pozitron emisyon tomografisi (PET) - bilgisayarlı tomografinin (BT) onkolojide kullanımı giderek artan öneme sahip olmaktadır. Çalışmamızda tümörün bazı özelliklerine göre 18 F-floro-2-deoksi-D-glukoz ( 18 F-FDG) tutulum yoğunluğu arasındaki ilişkiyi araştırmayı planladık. Gereç ve Yöntem: Çalışmamızda onkoloji kliniğimize meme kanseri teşhisi ile başvuran ve PET-BT çekimi yapılan 414 hastanın dosyası retrospektif incelendi. Çalışmaya 18-90 yaş aralığında olan meme kanserli hastalar dahil edildi. İkincil malignitesi olan, akli dengesi yerinde olmayan, 18 yaşından küçük ve 90 yaşından büyük hastalar çalışma dışı bırakıldı. Moleküler alt tiplere, tümör boyutlarına, vücut kitle indeksine ve proliferasyon indekslerine göre FDG tutulumları araştırıldı. Bulgular: Çalışmaya dahil edilen 414 hastanın yaş ortalaması 48.8 yıldı. Hastaların büyük çoğunluğunun alt tipi; invaziv duktal karsinom idi. Tanı anında 86 hasta metastatik evrede iken, 327 hasta lokal veya lokal ileri evredeydi. Çalışmada Ki-67 artışı ile FDG tutulumunun artışı arasında korelasyon saptandı ve istatiksel olarak anlamlı bulundu. Sonuç: Çalışmada tümör boyutu büyük olanlarda daha fazla FDG tulumu mevcut idi. Aynı şekilde proliferasyon indeksi artışında ve invaziv duktal karsinomda daha yüksek FDG tutulumu mevcut idi. Tümör özellikleri ile FDG tutulumları arasındaki ilişki gelecekte bireyselleştirilmiş tedavi için prediktif bir belirteç olarak kullanılabilir.

🔖

Cite This Article

SEZGİN, Y., KARHAN, O., İLERİ, S., EBİNÇ, S., BİLEN, E., ÜRÜN, M., YERLİKAYA, H. (2022). The Relationship Between Pet - CT and Tumor Features in Patients With Breast Cancer. Van Tıp Dergisi, Cilt: 29 - Sayı: 3, 337–343. https://ajindex.com/articles/645877

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. DeSantis, CE, Fedewa, SA, Goding Sauer, A Breast cancer statistics, 2015: Convergence of incidence rates between black and white women. CA Cancer J Clin 2016; 66: 31-42
  2. Allemani C, Sant M, Weir HK, Richardson L C, Baili P, Storm H, et al. Breast cancer survival in the US and Europe: a CONCORD high-resolution study. Int J Cancer 2013; 132: 1170-1181
  3. Kim I, Choi HJ, Ryu JM, Lee SK, Yu JH, Kim SW, et al. Prognostic Validation of the American Joint Committee on Cancer 8th Staging System in 24,014 Korean Patients with Breast Cancer 2018; 21:173- 181
  4. Czernin J, Allen-Auerbach M, Nathanson D, Ken Hermann, PET-CT in Oncology: Current Status and Perspectives 2013; 1:177-190
  5. Avril S, Muzic RF, Jr., Plecha D, Bryan J. Traughber, Shaveta Vinayak, Norbert Avril 18F-FDG PET-CT for Monitoring of Treatment Response in Breast Cancer. J Nucl Med 2016; 57 (ek 1 ):34S-39S
  6. Riedl CC, Pinker K, Ulaner GA, Leonard T. Ong, Pascal Baltzer, Maxine S. Jochelson, et al. Comparison of FDG-PET-CT and contrast-enhanced CT for monitoring therapy response in patients with metastatic breast cancer. Eur J Nucl Med Mol Imaging. 2017; 44:1428-1437
  7. Kitajima K, Miyoshi Y. Present and future role of FDG-PET-CT imaging in the management of breast cancer. Jpn J Radyol 2016; 34:167-180
  8. Segaert I, Mottaghy F, Ceyssens S, De Wever W, Stroobants S, Van Ongeval C, et al. Additional value of PET-CT in staging clinical stage IIB and III breast cancer. nozzle J 2010; 16:617-624
  9. Nakai T, Okuyama C, Kubota T Yamada K, Ushijima Y, Taniike K, et al. Pitfalls of FDG-PET for the diagnosis of osteoblastic bone metastases in patients with breast cancer. Eur J Nucl Med Mol Imaging 2005; 32:1253-1258
  10. Sun Z, Yi YL, Liu Y, Xiong J P, Chao Zhu He. Comparison of whole body PET-PETCT and conventional imaging procedures for distant metastasis staging in patients with breast cancer: A meta-analysis. Eur J Gynaecol Oncol 2015; 36:672-676
  11. Fornier M, Fumoleau The paradox of triple negative breast cancer: novel approaches to treatment. Breast J P (2011) 18: 41-51
  12. Metzger-Filho O, Tutt A, de Azambuja E, Saini KS, Viale G, Loi S, et al. Dissecting the heterogeneity of triple-negative breast cancer. J Clin Oncol 2012. 30: 1879-1887
  13. Groheux D, Espie M, Giacchetti S, Hindie E (2012) Performance of FDG PET-CT in the clinical management of breast cancer. Radiology 266: 388-405
  14. Bos R, van Der Hoeven JJM, van Der Wall E, Van Der Groep P, Van Diest PJ, ComansUrvi Josh